Key result
Statin prescribing for primary prevention in diabetes varies ~57% across clinical practices.
Why the study?
Practice-level variation in statin use among diabetic patients in cardiology practices was unknown.
Observational (n=215,193)
Yes
Effect estimate: MRR 1.57 (95% CI 1.52-1.61)
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Such wide variation illustrates the gap between guideline recommendations and real world practice. Health care providers manage similar diabetes patients differently. While some variation is OK, what we found is concerning and may ultimately affect clinical outcomes.”
“When these types of discussions happen, patients are more likely to receive evidence-based therapies including statins. Once one is prescribed, it's important that patients take them and report any problems to their healthcare provider.”
There is significant practice-level variation in statin prescription for diabetic patients without CVD, highlighting a gap in guideline-concordant care.
Statins reduce cardiovascular disease (CVD) and mortality risk in patients with diabetes [(1)][1]. Practice-level variation in statin use among diabetic patients in cardiology practices is unknown. Accordingly, we examined practice-level variation in statin therapy among 40- to 75-year-old patients
No takes yet. Share an insight, caveat, or question.
Pokharel et al. (2016) conducted an observational in Diabetes without cardiovascular disease (n=215,193). Statin therapy vs. No statin therapy was evaluated on Practice-level variation in statin prescription (Median Rate Ratio) (MRR 1.57, 95% CI 1.52-1.61). There was significant practice-level variation in statin prescription among diabetic patients without cardiovascular disease, with an adjusted median rate ratio of 1.57.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: